Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera
WSJ·2025-10-30 18:23Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors. ...
WSJ·2025-10-30 18:23
WSJ·2025-10-30 18:23